Antiplatelet and anticoagulant therapy for stroke prevention in patients with non-valvular atrial fibrillation: Evidence based strategies and new developments;Tratamiento antiagregante plaquetario y anticoagulante para la prevención del ictus en pacientes con fibrilación auricular no valvular: Nuevos avances basados en la evidencia

Revista Espanola de Cardiologia

Volumn 64, Issue 4, 2011, Pages 260-268

  Gersh, Bernard J ^a   Freedman, Jane E ^b   Granger, Christopher B ^c  

^a MAYO CLINIC   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT;

ANTICOAGULANT THERAPY; EDITORIAL; HEART ATRIUM FIBRILLATION; STROKE;

EID: 79953304224     PISSN: 03008932     EISSN: 15792242     Source Type: Journal    
DOI: 10.1016/j.recesp.2011.01.001     Document Type: Article

References (61)

1. Gersh BJ, Tsang TS, Seward JB. The changing epidemiology and natural history of nonvalvular atrial fibrillation: clinical implications. Trans Am Clin Climatol Assoc. 2004;115:149-59.
2. Tsang TS, Miyasaka Y, Barnes ME, Gersh BJ. Epidemiological profile of atrial fibrillation: a contemporary perspective. Prog Cardiovasc Dis. 2005;48:1-8. (Pubitemid 41368554)
3. Marinigh R, Lip GY, Fiotti N, Giansante C, Lane DA. Age as a risk factor for stroke in atrial fibrillation patients implications for thromboprophylaxis: Implications for thromboprophylaxis. J Am Coll Cardiol. 2010;56:827-37.
4. Miyasaka Y, Barnes ME, Gersh BJ, Cha SS, Seward JB, Bailey KR, et al. Time trends of ischemic stroke incidence and mortality in patients diagnosed with first atrial fibrillation in 1980 to 2000: report of a community-based study. Stroke. 2005;36:2362-6.
5. Tsang TS, Petty GW, Barnes ME, O'Fallon WM, Bailey KR, Wiebers DO, et al. The prevalence of atrial fibrillation in incident stroke cases and matched population controls in Rochester, Minnesota: changes over three decades. J Am Coll Cardiol. 2003;42:93-100. (Pubitemid 36760767)
6. Wolf PA, Benjamin EJ, Belanger AJ, Kannel WB, Levy D, D'Agostino RB. Secular trends in the prevalence of atrial fibrillation: The Framingham Study. Am Heart J. 1996;131:790-5. (Pubitemid 26116354)
7. Estes NA 3rd, Halperin JL, Calkins H, Ezekowitz MD, Gitman P, Go AS, et al., American College of Cardiology; American Heart Association Task Force on Performance Measures; Physician Consortium for Performance Improvement. ACC/AHA/Physician Consortium 2008 Clinical Performance Measures for Adults with Nonvalvular Atrial Fibrillation or Atrial Flutter: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures and the Physician Consortium for Performance Improvement (Writing Committee to Develop Clinical Performance Measures for Atrial Fibrillation) Developed in Collaboration with the Heart Rhythm Society. J Am Coll Cardiol. 2008;51:865-84.
8. Lloyd-Jones DM, Wang TJ, Leip EP, Larson MG, Levy D, Vasan RS, et al. Lifetime risk for development of atrial fibrillation: the Framingham Heart Study. Circulation. 2004;110:1042-6. (Pubitemid 39319000)
9. Miyasaka Y, Barnes ME, Bailey KR, Cha SS, Gersh BJ, Seward JB, et al. Mortality trends in patients diagnosed with first atrial fibrillation: a 21-year community-based study. J Am Coll Cardiol. 2007;49:986-92.
10. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991;22:983-8.
11. Jahangir A, Lee V, Friedman PA, Trusty JM, Hodge DO, Kopecky SL, et al. Long-term progression and outcomes with aging in patients with lone atrial fibrillation: a 30-year follow-up study. Circulation. 2007;115:3050-6. (Pubitemid 46956493)
12. Kopecky SL, Gersh BJ, McGoon MD, Whisnant JP, Holmes DR Jr, Ilstrup DM, et al. The natural history of lone atrial fibrillation. A population-based study over three decades. N Engl J Med. 1987;317:669-74. (Pubitemid 17138192)
13. Abhayaratna WP, Barnes ME, O'Rourke MF, Gersh BJ, Seward JB, Miyasaka Y, et al. Relation of arterial stiffness to left ventricular diastolic function and cardiovascular risk prediction in patients > or =65 years of age. Am J Cardiol. 2006;98:1387-92. (Pubitemid 44666649)
14. Tsang TS, Barnes ME, Gersh BJ, Bailey KR, Seward JB. Left atrial volume as a morphophysiologic expression of left ventricular diastolic dysfunction and relation to cardiovascular risk burden. Am J Cardiol. 2002;90:1284-9. (Pubitemid 35449471)
15. Tsang TS, Barnes ME, Gersh BJ, Takemoto Y, Rosales AG, Bailey KR, et al. Prediction of risk for first age-related cardiovascular events in an elderly population: the incremental value of echocardiography. J Am Coll Cardiol. 2003;42:1199-205. (Pubitemid 37188341)
16. Tsang TS, Gersh BJ, Appleton CP, Tajik AJ, Barnes ME, Bailey KR, et al. Left ventricular diastolic dysfunction as a predictor of the first diagnosed nonvalvular atrial fibrillation in 840 elderly men and women. J Am Coll Cardiol. 2002;40:1636-44. (Pubitemid 35253642)
17. Watson T, Shantsila E, Lip GY. Mechanisms of thrombogenesis in atrial fibrillation: Virchow's triad revisited. Lancet. 2009;373:155-66.
18. Heppell RM, Berkin KE, McLenachan JM, Davies JA. Haemostatic and haemodynamic abnormalities associated with left atrial thrombosis in non-rheumatic atrial fibrillation. Heart. 1997;77:407-11. (Pubitemid 27278416)
19. Lip GY, Lowe GD, Rumley A, Dunn FG. Increased markers of thrombogenesis chronic atrial fibrillation: effects of warfarin treatment. Br Heart 1995;73:527-33.
20. Lip GY, Lowe GD, Rumley A, Dunn FG. Fibrinogen and fibrin D-dimer levels paroxysmal atrial fibrillation: evidence for intermediate elevated levels intravascular thrombogenesis. Am Heart J. 1996;131:724-30. (Pubitemid 26119563)
21. Montoro-García S, Marín F, Lip GY. Thrombogenesis in lone atrial fibrillation: role for soluble P-selectin? Europace. 2011;13:3-4.
22. Stroke Risk in Atrial Fibrillation Working Group. Comparison of 12 risk stratification schemes to predict stroke in patients with nonvalvular atrial fibrillation. Stroke. 2008;39:1901-10.
23. Fang MC, Go AS, Chang Y, Borowsky L, Pomernacki NK, Singer DE. Comparison risk stratification schemes to predict thromboembolism in people with non-valvular atrial fibrillation. J Am Coll Cardiol. 2008;51:810-5. (Pubitemid 351253746)
24. Wysokinski WE, Ammash N, Sobande F, Kalsi H, Hodge D, McBane RD. Predicting left atrial thrombi in atrial fibrillation. Am Heart J. 2010;159:665-71.
25. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA. 2001;285:2864-70.
26. Healey JS, Hart RG, Pogue J, Hohnloser SH, De Caterina R, Flaker G, et al. Risks and benefits of oral anticoagulation compared with clopidogrel plus aspirin patients with atrial fibrillation according to stroke risk: the atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events (ACTIVE-W). Stroke. 2008;39:1482-6.
27. Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart 2010;31:2369-429.
28. Lip GY, Frison L, Halperin JL, Lane DA. Identifying patients at high risk for stroke despite anticoagulation: a comparison of contemporary stroke risk stratification schemes in an anticoagulated atrial fibrillation cohort. Stroke. 2010;41:2731-8.
29. Poli D, Lip GY, Antonucci E, Grifoni E, Lane D. Stroke risk stratification in a "Real-World" elderly anticoagulated atrial fibrillation population. J Cardiovasc Electrophysiol. 2011;22:25-30.
30. Singer DE, Fang MC, Go AS. CHA2DS2-VASc risk scheme: not ready for clinical use. Chest. 2010;138:1020.
31. Pisters R, Lane DA, Nieuwlaat R, De Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010;138:1093-100.
32. Wann L, Curtis A, January C. 2011 ACCF/AHA/HRS Focused Update on the Management of Patients With Atrial Fibrillation (Updating the 2006 Guideline). J Am Coll Cardiol. 2011;57:223-42.
33. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146:857-67. (Pubitemid 351650486)
34. Sato H, Ishikawa K, Kitabatake A, Ogawa S, Maruyama Y, Yokota Y, et al. Low-dose aspirin for prevention of stroke in low-risk patients with atrial fibrillation: Japan Atrial Fibrillation Stroke Trial. Stroke. 2006;37:447-51. (Pubitemid 43732003)
35. ACTIVE Investigators, Connolly SJ, Pogue J, Hart RG, Hohnloser SH, Pfeffer M, Chrolavicius S, et al. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med. 2009;360:2066-78.
36. ACTIVE Writing Group of the ACTIVE Investigators, Connolly S, Pogue J, Hart Pfeffer M, Hohnloser S, Chrolavicius S, et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet. 2006;367:1903-12.
37. Connolly SJ, Pogue J, Eikelboom J, Flaker G, Commerford P, Franzosi MG, et al. Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range. Circulation. 2008;118:2029-37.
38. Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial. Lancet. 1996;348:633-8.
39. Freedman JE, Gersh BJ. New therapies for stroke prevention in atrial fibrillation: the long road to enhanced efficacy. Circulation. 2009;120:1024-6.
40. Petersen P, Grind M, Adler J. Ximelagatran versus warfarin for stroke prevention in patients with nonvalvular atrial fibrillation. SPORTIF II: a dose-guiding, tolerability, and safety study. J Am Coll Cardiol. 2003;41:1445-51. (Pubitemid 36546266)
41. Matchar DB, Jacobson A, Dolor R, Edson R, Uyeda L, Phibbs CS, et al. Effect home testing of international normalized ratio on clinical events. N Engl J Med. 2010;363:1608-20.
42. Morgan CL, McEwan P, Tukiendorf A, Robinson PA, Clemens A, Plumb JM. Warfarin treatment in patients with atrial fibrillation: observing outcomes associated with varying levels of INR control. Thromb Res. 2009;124:37-41.
43. White HD, Gruber M, Feyzi J, Kaatz S, Tse HF, Husted S, et al. Comparison of outcomes among patients randomized to warfarin therapy according to anti-coagulant control: results from SPORTIF III and V. Arch Intern Med. 2007; 167:239-45.
44. Go AS, Hylek EM, Chang Y, Phillips KA, Henault LE, Capra AM, et al. Anti-coagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice? JAMA. 2003;290:2685-92.
45. Connolly SJ, Eikelboom J, O'Donnell M, Pogue J, Yusuf S. Challenges of establishing new antithrombotic therapies in atrial fibrillation. Circulation. 2007;116:449-55. (Pubitemid 47196550)
46. Jackson K, Gersh BJ, Stockbridge N, Fleming TR, Temple R, Califf RM, et al. Antithrombotic drug development for atrial fibrillation: proceedings, Washington, DC, July 25-27, 2005. Am Heart J. 2008;155:829-40.
47. Ellis DJ, Usman MH, Milner PG, Canafax DM, Ezekowitz MD. The first evaluation of a novel vitamin K antagonist, tecarfarin (ATI-5923), in patients with atrial fibrillation. Circulation. 2009;120:1029-35. 2 p following 1035.
48. Mann KG, Brummel K, Butenas S. What is all that thrombin for? J Thromb Haemost. 2003;1:1504-14.
49. Piccini JP, Lopes RD, Mahaffey KW. Oral factor Xa inhibitors for the prevention of stroke in atrial fibrillation. Curr Opin Cardiol. 2010;25:312-20.
50. Di Nisio M, Middeldorp S, Buller HR. Direct thrombin inhibitors. N Engl J Med. 2005;353:1028-40. (Pubitemid 41262337)
51. Agnelli G, Eriksson BI, Cohen AT, Bergqvist D, Dahl OE, Lassen MR, et al. Safety assessment of new antithrombotic agents: lessons from the EXTEND study on ximelagatran. Thromb Res. 2009;123:488-97.
52. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139-51.
53. Wallentin L, Yusuf S, Ezekowitz MD, Alings M, Flather M, Franzosi MG, et al. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet. 2010;376:975-83.
54. Diener HC, Connolly SJ, Ezekowitz MD, Wallentin L, Reilly PA, Yang S, et al. Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial. Lancet Neurol. 2010;9:1157-63.
55. APPRAISE-2 Apixaban in ACS Study Discontinued Due to Increased Bleeding [consultado 19/1/2011]. Disponible en: http://cardiobrief.org/2010/11/18/ appraise-2-apixaban-in-acs-study-discontinued-due-to-increased-bleeding
56. Connolly SJ, Harald A. AVERROES: Apixaban Versus Acetylsalicylic Acid (ASA) to Prevent Strokes [consultado 19/1/2011]. Disponible en: http://www. escardio.org/congresses/esc-2010/congress-reports/Pages/708-3- AVERROES.aspx
57. Holmes DR Jr, Schwartz RS. Left atrial appendage occlusion eliminates the need for warfarin. Circulation. 2009;120:1919-26.
58. Odell JA, Blackshear JL, Davies E, Byrne WJ, Kollmorgen CF, Edwards WD, et al. Thoracoscopic obliteration of the left atrial appendage: potential for stroke reduction? Ann Thorac Surg. 1996;61:565-9.
59. Whitlock RP, Healey JS, Connolly SJ. Left atrial appendage occlusion does not eliminate the need for warfarin. Circulation. 2009;120:1927-32.
60. Holmes DR, Reddy VY, Turi ZG, Doshi SK, Sievert H, Buchbinder M, et al. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial. Lancet. 2009;374:534-42.
61. Singer DE, Albers GW, Dalen JE, Fang MC, Go AS, Halperin JL, et al. Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133:S546-92.